Amundi Fate Therapeutics Inc Transaction History

Amundi

$253 Billion
Q2 2024

A detailed history of Amundi transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Amundi holds 4,990 shares of FATE stock, worth $17,814. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,990

Holding current value

$17,814

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $16,267 - $35,329	4,990 New	4,990 $16,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $19,775 - $51,863	-4,664 Reduced 39.47%	7,154 $40,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $690,495 - $1.67 Million	-70,030 Reduced 85.56%	11,818 $119,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $3.24 Million - $5.55 Million	-153,845 Reduced 65.27%	81,848 $1.93 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $2.17 Million - $5.17 Million	-121,846 Reduced 34.08%	235,693 $7.43 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $700,063 - $1.42 Million	-23,595 Reduced 6.19%	357,539 $14.1 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $885,996 - $1.19 Million	-18,520 Reduced 4.63%	381,134 $16.1 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $523,531 - $845,583	-8,833 Reduced 2.16%	399,654 $23.7 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $27.5 Million - $37.8 Million	408,487 New	408,487 $35.5 Million

Others Institutions Holding FATE

# of Institutions

190

Shares Held

123M

Call Options Held

15K

Put Options Held

14K

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$47 Million
2.82% of portfolio
Vanguard Group Inc Valley Forge, PA

10.6M
Shares

$37.7 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$36.1 Million
0.0% of portfolio
Boxer Capital, LLC San Diego, CA

8.22M
Shares

$29.3 Million
1.5% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$19.9 Million
0.6% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $346M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account